|
KMID : 0378019860290050087
|
|
New Medical Journal
1986 Volume.29 No. 5 p.87 ~ p.91
|
|
|
The Clinical Study of Emorfazone(Emazon^(®)) in Orthopedic Field
|
|
최일용/Choi, Il Yong
김준식/Kim, Joon Sik
|
|
|
Abstract
|
|
|
Emorfazone(Emazon®) Tab. is a potent antiinflammatory-analgesic drug developed i ´Pharmacological Research Institute of Morishita Pharmaceutical Co., Ltd. after an extensiv screening of pyridazinone derivatives and antagonizes the onset mechanism of pain b -inhibiting release of bradykinin.
To evaluate the therapeutic effectiveness and side reaction of Emorfazone(Emazon(D), a clinical study was carried out in 90 patients consisting of 30 lumbago, 30 scapulohumeral periarthritis´aind 30 shoulder-neck-arm syndrome.
The patient received daily dose of 600mg Emorfazone (Emazon®) for 14 days.
The results were as follows.:
1. The effect of Emorfazone(EmazonB) was "Markedly improved" in 38 patients (42.2%6),
""Moderately improved" in 37 patients(41.1%), "Slightly improved" in 11 patients (12.2%),
"Unchanged" in 4 patients(4.4%), and there was no "Aggravated" case, 75 patients (83.3°0;
were better than "Moderately improved" result.
2. There was decrease of ESR and no harmful effect on renal, hepatic and hematopoietic .function.
3. Side effects (indigestion, headache and insomnia) were observed in 3 patients(3.3%), but the symptom was relieved with discontinuation of drug.
It was concluded that Emorfazone(Emazon(B) is useful drug in orthopedic fields for the management of lumbago, scapulohumeral periarthritis and shoulder-neck-arm syndrome.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|